GSK Wins EU Nod for First Ultra-Long-Acting Biologic in Severe Asthma

The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

GSK has secured European Commission approval for Exdensur (depemokimab), the first ultra-long-acting biologic in the EU for severe asthma with type 2 inflammation and for severe chronic rhinosinusitis with nasal polyps, as an add-on to existing therapies. The decision, underpinned by four phase III trials showing sustained efficacy and safety with twice-yearly dosing, strengthens GSK’s respiratory franchise and introduces a differentiated option that could shift treatment standards for millions of Europeans with inadequately controlled respiratory disease, while positioning the drug for broader use in other type 2 inflammatory indications under ongoing late-stage development.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £24.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK is a global biopharma company focused on respiratory and inflammatory diseases, with an industry-leading portfolio of vaccines, targeted biologics and inhaled medicines. The company aims to redefine respiratory care, improving outcomes for patients with asthma, COPD and rarer conditions by targeting underlying disease mechanisms and preventing progression.

Average Trading Volume: 8,707,514

Technical Sentiment Signal: Buy

Current Market Cap: £87.35B

For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.